Egeler, M. D.
van de Poll-Franse, L. V.
Tissier, R.
Rogiers, A.
Boers-Sonderen, M. J.
van den Eertwegh, A. J.
Hospers, G. A.
de Groot, J. W. B.
Aarts, M. J. B.
Kapiteijn, E.
Piersma, D.
Vreugdenhil, G.
van der Veldt, A. A.
Suijkerbuijk, K. P. M.
Neyns, B.
Janssen, K. J.
Blank, C. U.
Retèl, V. P.
Boekhout, A. H.
Funding for this research was provided by:
Bristol-Myers Squibb (CA209483)
Article History
Accepted: 16 April 2023
First Online: 20 April 2023
Declarations
:
: A.H. Boekhout received a research grant from Bristol-Myers Squibb for this study. A. Rogiers: Bristol-Myers Squibb and Merck Sharp & Dome (consulting and advisory board). M. Boers-Sonderen: Bristol-Myers Squibb, Pierre Fabre, and Roch (advisory board). A.J.M. van den Eertwegh: Sanofi, Bristol-Myers Squibb and Roche (study grant); MSD Oncology, Roche, Pfizer, and Sanofi (travel expenses); Bristol-Myers Squibb (honoraria); Bristol-Myers Squibb, MSD Oncology, Amgen, Roche, Novartis, Sanofi, Pfizer, Ipsen, and Merck (advisory board). G.A. Hospers: Bristol-Myers Squibb, Amgen, Roche, Pfizer, Novartis, MSD (consulting and advisory board) and received research grants from Bristol-Myers Squibb and Seerave. J.W.B. de Groot: Bristol-Myers Squibb, MSD Oncology, Novartis, Pierre Fabre and Servier (consulting and advisory board). M.J.B. Aarts: Bristol-Myers Squibb, Merck Sharp & Dome, Pfizer, Pierre Fabre, Astellas, Ipsen and Novartis (consulting). K.P.M. Suijkerbuijk reports personal fees as a consult advisor (paid to institution) advisory role: Roche, Novartis, MSD, BMS, Pierre Fabre (all paid to institution). H.W. Kapiteijn: Amgen, Bristol-Myers Squibb, Novartis, Roche, Merck, Pierre-Fabre, EISAI, Bayer and Genzyme-Sanofi (consulting and advisory board); and received a research grant from Bristol-Myers Squibb. A.A.M. van der Veldt: Bayer (travel expenses) and Bristol-Myers Squibb, Merck Sharp & Dome, Roche, Novartis, Pierre Fabre, Pfizer, Sanofi, Eisai and Ipsen (consulting and advisory board). K.J. Jansen is working at Bristol-Myers Squibb. B. Neyns: Bristol-Myers Squibb, Merck Sharp & Dome, Novartis, and Roche (honoraria), and Bristol-Myers Squibb, Merck Sharp & Dome, Novartis, Roche, Speakers’ Bureau-Novartis (consulting and advisory), and Amgen, Bristol-Myers Squibb, Merck Sharp & Dome, Novartis, and Roche (travel expenses). C.U. Blank reports personal fees as a consultant advisor (paid to the institution) or travel support. All other authors declare no competing interests (Vreugdenhil, Tissier, Djura, and Retèl).
: The study was approved by the institutional review board of the NKI (METC16.0634) and meets the institutional review board standards.
: This study was performed in accordance with the Declaration of Helsinki.